Compound class:
Synthetic organic
Comment: Compound 3 is reported as a substrate selective inhibitor of cyclooxygenase-2 (COX-2) [1]. It preferentially inhibits conversion (by oxygenation) of the endocannabinoid 2-arachidonoylglycerol (2-AG) to prostaglandin glyceryl ester (PG-G) compared to oxygenation of arachidonic acid (AA) into prostaglandins, which is predicted to increase endocannabinoid levels in the brain and mediate anti-stress/anti-anxiety effects.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Uddin MJ, Xu S, Crews BC, Ghebreselasie K, Banerjee S, Marnett LJ. (2020)
Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors. ACS Med Chem Lett, ARTICLES ASAP. DOI: 10.1021/acsmedchemlett.9b00555 |